Lastly, to determine whether blocking TIGIT could enhance the anti-tumor effect of anti-MASL CAR-T cells in vivo, six-week-old B-NDG mice were reared for subcutaneous infused of HelaCD155 cells for tumorigenesis in vivo. Here, MAS1L is linked to neoplasm.